Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: Promise and challenge

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cancer in the United States and worldwide. In spite of the rapid progression in personalized treatments, the overall survival rate of lung cancer patients is still suboptimal. Over the past decade, tremendous efforts have been focused on the discovery of protein biomarkers to facilitate the early detection and monitoring of lung cancer progression during treatment. In addition to tumor tissues and cancer cell lines, a variety of biological material has been studied. Particularly in recent years, studies using fluid-based specimen or so-called "fluid-biopsy" specimens have progressed rapidly. Fluid specimens are relatively easier to collect than tumor tissue, and they can be repeatedly sampled during the disease progression. Glycoproteins are the major content of fluid specimens and have long been recognized to play fundamental roles in many physiological and pathological processes. In this review, we focus the discussion on recent advances of glycoproteomics, particularly in the identification of potential glyco protein biomarkers using fluid-based specimens in lung cancer. The purpose of this review is to summarize current strategies, achievements, and perspectives in the field. This insight will highlight the discovery of tumor-associated glycoprotein biomarkers in lung cancer and their potential clinical applications.

Original languageEnglish (US)
Pages (from-to)55-69
Number of pages15
JournalProteomics - Clinical Applications
Volume7
Issue number1-2
DOIs
StatePublished - Jan 2013

Fingerprint

Biomarkers
Tumor Biomarkers
Lung Neoplasms
Fluids
Tumors
Neoplasms
Proteins
Glycoproteins
Tissue
Physiological Phenomena
Biopsy
Pathologic Processes
Biological materials
Disease Progression
Survival Rate
Cells
Cell Line
Monitoring
Therapeutics

Keywords

  • Body fluids
  • Glycoproteins
  • Glycoproteomics
  • Nonsmall cell lung cancer (NSCLC)
  • Protein biomarkers

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

@article{8d992ce7480848538ccbc5e31f0d112d,
title = "Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: Promise and challenge",
abstract = "Lung cancer is the leading cancer in the United States and worldwide. In spite of the rapid progression in personalized treatments, the overall survival rate of lung cancer patients is still suboptimal. Over the past decade, tremendous efforts have been focused on the discovery of protein biomarkers to facilitate the early detection and monitoring of lung cancer progression during treatment. In addition to tumor tissues and cancer cell lines, a variety of biological material has been studied. Particularly in recent years, studies using fluid-based specimen or so-called {"}fluid-biopsy{"} specimens have progressed rapidly. Fluid specimens are relatively easier to collect than tumor tissue, and they can be repeatedly sampled during the disease progression. Glycoproteins are the major content of fluid specimens and have long been recognized to play fundamental roles in many physiological and pathological processes. In this review, we focus the discussion on recent advances of glycoproteomics, particularly in the identification of potential glyco protein biomarkers using fluid-based specimens in lung cancer. The purpose of this review is to summarize current strategies, achievements, and perspectives in the field. This insight will highlight the discovery of tumor-associated glycoprotein biomarkers in lung cancer and their potential clinical applications.",
keywords = "Body fluids, Glycoproteins, Glycoproteomics, Nonsmall cell lung cancer (NSCLC), Protein biomarkers",
author = "Li, {Qing Kay} and Edward Gabrielson and Askin, {Frederic B} and Chan, {Daniel Wan-Yui} and Hui Zhang",
year = "2013",
month = "1",
doi = "10.1002/prca.201200105",
language = "English (US)",
volume = "7",
pages = "55--69",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "1-2",

}

TY - JOUR

T1 - Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers

T2 - Promise and challenge

AU - Li, Qing Kay

AU - Gabrielson, Edward

AU - Askin, Frederic B

AU - Chan, Daniel Wan-Yui

AU - Zhang, Hui

PY - 2013/1

Y1 - 2013/1

N2 - Lung cancer is the leading cancer in the United States and worldwide. In spite of the rapid progression in personalized treatments, the overall survival rate of lung cancer patients is still suboptimal. Over the past decade, tremendous efforts have been focused on the discovery of protein biomarkers to facilitate the early detection and monitoring of lung cancer progression during treatment. In addition to tumor tissues and cancer cell lines, a variety of biological material has been studied. Particularly in recent years, studies using fluid-based specimen or so-called "fluid-biopsy" specimens have progressed rapidly. Fluid specimens are relatively easier to collect than tumor tissue, and they can be repeatedly sampled during the disease progression. Glycoproteins are the major content of fluid specimens and have long been recognized to play fundamental roles in many physiological and pathological processes. In this review, we focus the discussion on recent advances of glycoproteomics, particularly in the identification of potential glyco protein biomarkers using fluid-based specimens in lung cancer. The purpose of this review is to summarize current strategies, achievements, and perspectives in the field. This insight will highlight the discovery of tumor-associated glycoprotein biomarkers in lung cancer and their potential clinical applications.

AB - Lung cancer is the leading cancer in the United States and worldwide. In spite of the rapid progression in personalized treatments, the overall survival rate of lung cancer patients is still suboptimal. Over the past decade, tremendous efforts have been focused on the discovery of protein biomarkers to facilitate the early detection and monitoring of lung cancer progression during treatment. In addition to tumor tissues and cancer cell lines, a variety of biological material has been studied. Particularly in recent years, studies using fluid-based specimen or so-called "fluid-biopsy" specimens have progressed rapidly. Fluid specimens are relatively easier to collect than tumor tissue, and they can be repeatedly sampled during the disease progression. Glycoproteins are the major content of fluid specimens and have long been recognized to play fundamental roles in many physiological and pathological processes. In this review, we focus the discussion on recent advances of glycoproteomics, particularly in the identification of potential glyco protein biomarkers using fluid-based specimens in lung cancer. The purpose of this review is to summarize current strategies, achievements, and perspectives in the field. This insight will highlight the discovery of tumor-associated glycoprotein biomarkers in lung cancer and their potential clinical applications.

KW - Body fluids

KW - Glycoproteins

KW - Glycoproteomics

KW - Nonsmall cell lung cancer (NSCLC)

KW - Protein biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84872740453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872740453&partnerID=8YFLogxK

U2 - 10.1002/prca.201200105

DO - 10.1002/prca.201200105

M3 - Article

C2 - 23112109

AN - SCOPUS:84872740453

VL - 7

SP - 55

EP - 69

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 1-2

ER -